(SUS) Surgical Science Sweden - Ratings and Ratios

Surgical Science Sweden AB is a pioneering medical technology company that develops and markets cutting-edge virtual reality simulators for evidence-based medical training globally, with a presence in Europe, North and South America, Asia, and other international markets. The companys comprehensive product portfolio includes a range of simulators for various medical specialties, such as endovascular training, arthroscopic surgery, bronchoscopy, GI endoscopy, hysteroscopy, endourology, laparoscopic surgery, robotic surgery, and ultrasound training.

The companys simulators, including Angio Mentor, BRONCH Mentor, ARTHRO Mentor, GI Mentor, HYST Mentor, URO Mentor, EndoSim, FlexVR, and LAP Mentor, provide a realistic and immersive training experience for medical professionals, allowing them to hone their skills in a controlled and risk-free environment. Additionally, Surgical Sciences LapSim training system, which includes LapSim Haptic, LapSim essence, and LapSim360, offers a range of laparoscopic training solutions. The companys other products, such as MentorLearn, LapSim ST, PELVIC Mentor, Perc Mentor, RobotiX Mentor, Simball Box, Spine Mentor, TEE Express, TraumaVR, and Ultrasound Mentor, further expand its offerings in the medical simulation market.

With a strong foundation established since its incorporation in 1997 in Gothenburg, Sweden, Surgical Science has grown to become a leading player in the medical technology industry. As a publicly traded company (ST:SUS), its financial performance and market dynamics are closely watched by investors. Based on the available and , a forecast can be made. The stocks recent price movement, with a last price of 151.80 and an ATR of 5.96 (3.93%), indicates a relatively stable trend. The SMA20, SMA50, and SMA200 values suggest a positive short-term and long-term outlook. Considering the companys market cap of 7347.77M SEK and a forward P/E of 31.06, it is likely that the stock will continue to grow, driven by the increasing demand for medical simulation technologies. A potential price target could be around 170-180, representing a 12-19% increase from the current price.